Related Experiment Video
Updated: Nov 19, 2025
07:47
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
1.9K
Development and validation of prognostic markers in sarcomas base on a multi-omics analysis
Yongchun Song1, Kui Yang2, Tuanhe Sun1
1Department of Oncology Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an, 710061, Shaanxi, China.
BMC Medical Genomics
|January 29, 2021
Summary
This study reveals four distinct molecular subtypes of sarcoma, with specific genes like ENO1, ACVRL1, and APBB1IP serving as key prognostic markers. These findings enhance understanding of sarcoma
Area of Science:
- Oncology
- Genomics
- Epigenetics
Background:
- Sarcomas exhibit genomic aberrations in DNA copy number and DNA methylation, with transcriptome imbalances driving disease progression.
- The relationship between DNA copy number abnormalities and epigenetic DNA methylation in sarcomas remains unclear, necessitating integrated genomic and epigenomic analysis.
Purpose of the Study:
- To comprehensively analyze sarcoma development by integrating genomic and epigenomic data.
- To identify molecular subtypes and key prognostic biomarkers for sarcoma.
- To elucidate the multilayered pathobiology of sarcomas through multiomics analysis.
Main Methods:
- Utilized RNA sequencing, copy number variation (CNV), and methylation data from TCGA and GEO databases.
- Analyzed the association between methylation and CNV to identify methylation-related genes (MET-Gs) and CNV abnormality-related genes (CNV-Gs).
- Integrated multiomics data to define molecular subtypes and their clinical/molecular characteristics, followed by biomarker validation.
Main Results:
- Identified 5354 CNV-Gs and 4042 MET-Gs with high consistency.
- Discovered four molecular subtypes (iC1-iC4) with distinct prognostic significance; iC2 showed the worst prognosis, while iC4 indicated an immune-enhancing state.
- Determined three prognostic markers: ENO1 (correlated with CNV, high in iC2), ACVRL1 and APBB1IP (negatively correlated with methylation, high in iC4).
Conclusions:
- This integrated genomic and epigenomic analysis provides novel insights into sarcoma pathobiology.
- The identified molecular subtypes and prognostic markers advance the understanding of sarcoma's molecular mechanisms.
- The study offers a foundation for improved diagnostic and therapeutic strategies in sarcoma treatment.
Related Concept Videos
02:07Tumor Progression
6.9K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.9K
03:03mTOR Signaling and Cancer Progression
4.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.1K